Brighton and Sussex Medical School, University of Sussex.
Rheumatology Department, The Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
Rheumatology (Oxford). 2021 Dec 1;60(12):5843-5853. doi: 10.1093/rheumatology/keab162.
Cartilage and bone damage in RA are associated with elevated IL-1β. The effects of IL-1β can be reduced by biological therapies that target IL-1β or TNF-α. However, the mechanisms responsible for increased IL-1β and the effect of anti-TNF-α have not been fully elucidated. Recently, sterile-α and armadillo motif containing protein (SARM) was identified as a negative regulator of toll-like receptor (TLR) induced IL-1β secretion through an interaction with the inflammasome. This study set out to investigate SARM during TLR-induced IL-1β secretion in RA peripheral blood monocytes and in patients commencing anti-TNF-α treatment.
Monocytes were isolated from RA patients and healthy controls; disease activity was measured by DAS28. IL-1β secretion was measured by ELISA following TLR1/2, TLR4 and TLR7/8 stimulation. The mRNA expression of SARM1, IL-1β and the components of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome were measured by quantitative PCR. SARM protein expression was measured by western blotting.
TLR1/2 activation induced elevated IL-1β in RA monocytes compared with healthy controls (P = 0.0009), which negatively correlated with SARM1 expression (P = 0.0086). Lower SARM expression also correlated with higher disease activity (P = 0.0246). Additionally, patients responding to anti-TNF-α treatment demonstrated a rapid upregulation of SARM, which was not observed in non-responders.
Together, these data highlight a potential contribution from SARM to RA pathophysiology where decreased SARM may lead to elevated IL-1β associated with RA pathogenesis. Furthermore, the data additionally present a potential mechanism by which TNF-α blockade can modify IL-1β secretion.
类风湿关节炎(RA)中的软骨和骨损伤与白细胞介素-1β(IL-1β)升高有关。靶向 IL-1β 或肿瘤坏死因子-α(TNF-α)的生物疗法可以降低 IL-1β 的作用。然而,导致 IL-1β 升高的机制以及抗 TNF-α 的作用尚未完全阐明。最近,无菌-α 和盔蛋白重复包含蛋白(SARM)被鉴定为通过与炎症小体相互作用,成为负调控 Toll 样受体(TLR)诱导的 IL-1β 分泌的分子。本研究旨在探讨 SARM 在 RA 外周血单核细胞和开始接受抗 TNF-α 治疗的患者中 TLR 诱导的 IL-1β 分泌中的作用。
从 RA 患者和健康对照者中分离单核细胞;通过 DAS28 测量疾病活动度。TLR1/2、TLR4 和 TLR7/8 刺激后,通过 ELISA 测量 IL-1β 的分泌。通过定量 PCR 测量 SARM1、IL-1β 和 NOD 样受体家族含 pyrin 结构域 3(NLRP3)炎症小体的组成部分的 mRNA 表达。通过 Western blot 测量 SARM 蛋白表达。
与健康对照组相比,TLR1/2 激活诱导 RA 单核细胞中升高的 IL-1β(P = 0.0009),这与 SARM1 表达呈负相关(P = 0.0086)。较低的 SARM 表达也与较高的疾病活动度相关(P = 0.0246)。此外,对 TNF-α 拮抗剂治疗有反应的患者迅速上调 SARM,而无反应者则未观察到这种情况。
这些数据共同强调了 SARM 对 RA 病理生理学的潜在贡献,其中 SARM 减少可能导致与 RA 发病机制相关的升高的 IL-1β。此外,数据还提供了一种潜在的机制,即 TNF-α 阻断可以改变 IL-1β 的分泌。